Nabriva Therapeutics PLC (NBRV)
1.46
-0.17
(-10.43%)
USD |
NASDAQ |
Jun 02, 16:00
Nabriva Therapeutics Enterprise Value: 3.418M for June 2, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 02, 2023 | 3.418M |
| June 01, 2023 | 3.962M |
| May 31, 2023 | 3.866M |
| May 30, 2023 | 3.898M |
| May 26, 2023 | 3.706M |
| May 25, 2023 | 3.866M |
| May 24, 2023 | 4.026M |
| May 23, 2023 | 4.251M |
| May 22, 2023 | 4.026M |
| May 19, 2023 | 4.987M |
| May 18, 2023 | 4.058M |
| May 17, 2023 | 4.225M |
| May 16, 2023 | 3.994M |
| May 15, 2023 | 4.090M |
| May 12, 2023 | 4.251M |
| May 11, 2023 | 4.203M |
| May 10, 2023 | 4.312M |
| May 09, 2023 | 4.090M |
| May 08, 2023 | 3.514M |
| May 05, 2023 | 4.251M |
| May 04, 2023 | 4.122M |
| May 03, 2023 | 3.850M |
| May 02, 2023 | 3.684M |
| May 01, 2023 | 3.866M |
| April 28, 2023 | 3.867M |
| Date | Value |
|---|---|
| April 27, 2023 | 3.866M |
| April 26, 2023 | 3.866M |
| April 25, 2023 | 3.802M |
| April 24, 2023 | 3.738M |
| April 21, 2023 | 4.058M |
| April 20, 2023 | 3.994M |
| April 19, 2023 | 3.962M |
| April 18, 2023 | 3.898M |
| April 17, 2023 | 3.610M |
| April 14, 2023 | 3.546M |
| April 13, 2023 | 3.739M |
| April 12, 2023 | 3.642M |
| April 11, 2023 | 3.707M |
| April 10, 2023 | 3.866M |
| April 06, 2023 | 4.347M |
| April 05, 2023 | 3.834M |
| April 04, 2023 | 4.235M |
| April 03, 2023 | 4.187M |
| March 31, 2023 | 4.337M |
| March 30, 2023 | -1.686M |
| March 29, 2023 | -1.496M |
| March 28, 2023 | -1.750M |
| March 27, 2023 | -1.622M |
| March 24, 2023 | -1.590M |
| March 23, 2023 | -1.462M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.58M
Minimum
Dec 24 2018
151.65M
Maximum
Apr 08 2019
39.92M
Average
28.96M
Median
Jan 21 2021
Enterprise Value Benchmarks
| Avadel Pharmaceuticals PLC | 1.095B |
| Medtronic PLC | 128.06B |
| Jazz Pharmaceuticals PLC | 12.77B |
| Iterum Therapeutics PLC | -6.028M |
| Mallinckrodt PLC | 2.638B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.70M |
| Revenue (Quarterly) | 7.59M |
| Total Expenses (Quarterly) | 16.06M |
| EPS Diluted (Quarterly) | -2.72 |
| Gross Profit Margin (Quarterly) | 41.53% |
| Profit Margin (Quarterly) | -114.6% |
| Earnings Yield | -1.32K% |
| Normalized Earnings Yield | -1315.07 |